NSAID Risk in Long-Duration Claims
Identify and manage chronic NSAID toxicity in injury recovery
Published: 3 April 2026 | Updated: 3 April 2026
Why Long-Term NSAIDs Matter in Claims Management
Non-steroidal anti-inflammatory drugs (NSAIDs) are ubiquitous in personal injury claims. A claimant with ongoing musculoskeletal pain, arthralgia, or inflammatory symptoms naturally receives an NSAID. The problem is not short-term NSAID use, but rather indefinite continuation without review or risk mitigation. After 6, 12, or 24 months on daily NSAIDs, serious adverse events emerge: gastrointestinal ulceration, acute kidney injury, cardiovascular events, and iatrogenic anemia. These complications extend claims duration, generate new medical costs, and (critically for you) are often preventable with proactive monitoring and deprescribing. As an insurer, understanding chronic NSAID risk and implementing governance protocols around long-term use is essential for protecting claimant safety and controlling costs.
NSAID Pharmacology and Long-Term Risk
NSAIDs inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and thus inflammation and pain. However, prostaglandins serve protective functions: in the stomach, they maintain mucosal integrity; in the kidney, they regulate blood flow and glomerular filtration; in blood vessels, they influence thrombotic balance. Chronic NSAID use suppresses these protective functions, leading to organ damage.
Major Adverse Effects of Chronic NSAID Use
Gastrointestinal Toxicity
NSAID-related ulcers and bleeding occur in 2 to 4 percent of chronic users annually. Some claimants experience occult bleeding (manifesting as iron-deficiency anemia) without overt symptoms. Older claimants have 2 to 4-fold elevated risk. History of peptic ulcer disease increases risk further. In claims with limited gastroprotection (no proton pump inhibitor or H2 blocker), gastrointestinal bleeding becomes a costly complication requiring hospitalization, transfusion, and endoscopy.
Acute Kidney Injury and Chronic Kidney Disease
Chronic NSAID use directly impairs renal function. Claimants with pre-existing renal disease, diabetes, hypertension, or volume depletion face highest risk. Presentation ranges from asymptomatic creatinine elevation to acute kidney injury requiring dialysis support. NSAID-induced renal damage is often irreversible; function may improve with cessation but rarely normalizes completely. This represents long-term morbidity for the claimant and extended liability for you.
Cardiovascular Events
Chronic NSAID use, particularly at higher doses and longer durations, increases myocardial infarction and stroke risk. Some NSAIDs (notably rofecoxib, withdrawn) carry higher cardiovascular risk than others. Traditional NSAIDs like ibuprofen carry moderate risk; celecoxib, lower risk. In older claimants or those with cardiovascular risk factors, chronic NSAID use presents genuine threat of acute cardiovascular event, complicating claims and creating new medical dependencies.
Fluid Retention and Hypertension
NSAIDs cause sodium and water retention, elevating blood pressure. Claimants on antihypertensive medication may see reduced drug efficacy. Some develop new hypertension or worsening heart failure on chronic NSAIDs. This is particularly problematic in claims with multiple comorbidities where blood pressure control is already challenging.
NSAID-Induced Anemia
Chronic NSAID use causes iron-deficiency anemia via occult gastrointestinal bleeding and, less commonly, hemolytic or hypoplastic mechanisms. Anemia impairs functional capacity and energy. A claimant with work-return objectives needs robust hemoglobin; NSAID-induced anemia undermines this goal and often requires iron supplementation or transfusion.
Risk Stratification for Chronic NSAID Use
| Risk Factor | Gastrointestinal Risk | Renal Risk | Cardiovascular Risk |
|---|---|---|---|
| Age over 65 | 2 to 4-fold increased | 2 to 3-fold increased | Increased baseline risk |
| History of peptic ulcer disease | 5 to 10-fold increased | Not directly related | Not directly related |
| Concurrent anticoagulation or antiplatelet | 3 to 4-fold increased | Moderate increase | Amplified risk |
| Renal impairment (eGFR under 60) | Moderate increase | Severe increase; contraindicated | Increased risk |
| Diabetes or hypertension | Moderate increase | 3 to 5-fold increased | Increased baseline risk |
| Heart failure or significant cardiovascular disease | Moderate increase | Severe increase | Contraindicated or high risk |
Monitoring and Governance for Chronic NSAID Users
Mandatory Monitoring Protocol
At initiation (baseline): Age, cardiovascular risk factors, renal function (creatinine, eGFR), blood pressure, hemoglobin, history of ulcer disease. Document indication and expected duration.
At 4 weeks: Clinical assessment. GI symptoms? Edema? Blood pressure shift? Adjust indication or risk mitigation if needed.
At 8 weeks: If plan is continued use beyond 12 weeks, initiate gastroprotection (PPI or H2 blocker) and schedule monitoring.
At 12 weeks: If still using daily NSAID, mandatory renal function (creatinine, eGFR) and hemoglobin repeat. High cardiovascular risk claimants should have this earlier.
Every 3 to 6 months thereafter: Renal function and hemoglobin. Reassess indication; explore deprescribing. Annually or at any acute illness: repeat labs plus blood pressure.
Gastroprotection Strategy
If daily NSAID use extends beyond 8 weeks, particularly in claimants over 65, those with ulcer history, or those on anticoagulation, gastroprotection is mandatory. Options include:
- Proton pump inhibitors (PPI): Omeprazole 20mg or esomeprazole 20mg daily. Most effective; reduces ulcer risk by 70 to 80 percent. Monitor for long-term use complications: hypomagnesemia, vitamin B12 deficiency, osteoporosis.
- H2 receptor antagonists: Ranitidine (if available) or famotidine. Less effective than PPI but adequate for moderate risk.
- Misoprostol: Rarely used due to side effects and need for multiple daily doses; reserved for high-risk patients intolerant of PPI.
Deprescribing Chronic NSAIDs
NSAIDs are overused in chronic pain management. Many claimants can achieve pain control with alternatives:
Alternatives to Chronic NSAID Therapy
- Paracetamol: Safe for chronic use (up to 4g daily) in claimants without liver disease. Often combined with NSAIDs; can replace NSAID monotherapy.
- Topical NSAIDs: Diclofenac, ibuprofen, or piroxicam gels/patches deliver local NSAID effect without systemic absorption. Excellent for localized joint or muscle pain; minimal systemic risk.
- Weak opioids: Codeine or tramadol as adjuncts if paracetamol alone insufficient. Carry their own risks but avoid NSAID systemic toxicity.
- Physical therapies: Physiotherapy, exercise, manual therapy address pain drivers. Often more effective long-term than medication alone.
- Psychological approaches: Pain psychology or mindfulness-based approaches support chronic pain management without medication burden.
Deprescribing Chronic NSAIDs
Step 1: Document baseline pain and function. VAS pain score, functional capacity, work status. This establishes whether deprescribing will impair recovery.
Step 2: Initiate alternative pain management. Start paracetamol, topical NSAIDs, physiotherapy, or other non-NSAID options. Allow 2 to 4 weeks for alternative to take effect.
Step 3: Reduce NSAID by 25 to 50 percent. Maintain paracetamol and alternatives. Monitor pain, function, and GI symptoms.
Step 4: Further reduce or cease NSAID. Some claimants successfully switch to paracetamol or topical agent alone. Others require low-dose NSAID maintenance with gastroprotection.
Step 5: Monitor post-cessation. Renal function and hemoglobin should improve over 4 to 12 weeks. Blood pressure may normalize. Document improvements.
Insurer Governance: NSAID Protocol
- Initial prescription (0 to 8 weeks): Approve short-term NSAID for acute pain or injury-related inflammation without requiring pre-authorization.
- At 8 weeks: Request pharmacy review if claimant still on daily NSAID. Document indication and expected duration.
- At 12 weeks: Initiate monitoring protocol (renal function, hemoglobin, blood pressure). If use extends beyond 12 weeks, mandate gastroprotection.
- At 6 months: Reassess indication. Explore alternatives. Request deprescribing plan if risk exceeds benefit.
- Beyond 12 months: Any daily NSAID use requires documented justification, active monitoring, and gastroprotection. No automatic renewal without review.
- High-risk claimants: Age over 65, prior ulcer, renal disease, anticoagulation: accelerate monitoring and deprescribing timeline.
Preventing Complications
Many NSAID-related complications are preventable with proactive governance:
- Gastroprotection: Reduces ulcer and bleeding risk by 70 to 80 percent
- Regular monitoring: Catches renal impairment or anemia before clinical decompensation
- Timely deprescribing: Eliminates ongoing risk once indication no longer justified
- Alternative exploration: Identifies non-NSAID pain management options that may be more effective
Is your claimant on chronic NSAIDs without gastroprotection or monitoring?
IMM's medication reviews identify NSAID toxicity risk, ensure appropriate monitoring, and guide deprescribing to safer alternatives. We work with your team to optimize pain management while protecting renal function, cardiovascular health, and gastrointestinal safety.
Request a Medication Review
